Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer

Seoul National University Hospital208 enrolled

Overview

Preoperative letrozole versus letrozole with metformin in postmenopausal Estrogen receptor positive breast cancer patients Phase II multicenter 1:1 randomized clinical trial Total 208 patients Primary endpoint Clinical response rate Secondary endpoint Pathologic complete response rate Breast conserving surgery rate Percent mammographic density change Ki67(%) change after 4week medication of 2nd core needle biopsy Toxicity profile of neoadjuvant letrozole, metformin

To identify the anti-tumor effect of metformin with preoperatively given letrozole in postmenopausal estrogen receptor positive breast cancer patients

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

208

Conditions

Hormone Receptor Positive Malignant Neoplasm of Breast

Interventions

MetforminDRUG

Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks

PlaceboDRUG

Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Estrogen receptor positive breast cancer * Clinically measurable tumor size(stage II/III) * No evidence of distant metastasis * Postmenopause women 'Age≥60yr' OR 'previous bilateral oophorectomy' OR 'FSH\>30 with no bleeding history within 1yr' * ECOG 0-2 * Adequate hepatorenal, bone marrow function 'serum Cr\<1.4mg/dL' AND 'Bilirubin\< upper limit of normal x 1.5 AND 'AST/ALT \< upper limit of normal x 1.8 AND 'ALP \< upper limit of normal x 1.8 AND 'Hemoglobin \>10 g/dL' AND 'ANC \>1,500/mm3' AND 'Platelet \>100,000/mm3' * Spontaneous signed into the written informed consent Exclusion Criteria: * Who does not meet the above inclusion criteria * History of other carcinoma * Uncontrolled infection * History of psychiatric, epileptic disease * Male breast cancer * Diabetes 'HbA1c≥6.5' OR 'FBS≥126mg/dL' * Hypersensitivity or intolerance to metformin * Risk of metformin associated lactic acidosis 'Congestive heart disease of NYHA Class llll/IV' OR 'History of other acidosis' OR 'Alcohol intake more than either 3 bottles beer OR 1 bottle Soju' * During medication of metformin, sulfonylureas, thiazolidinediones, insulin * Diffuse microcalcification in mammogram * Multiple OR bilateral OR inflammatory breast cancer * Chemotherapy or endocrine therapy within 2yr due to history of breast cancer

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Clinical response rate

Comparing with RECIST 1.1 From baseline to 24week(after completing medication, preoperatively)

Time frame: 24week(after completing medication, preoperatively)

Secondary Outcomes

Pathologic complete response rate

In case that under postoperative biopsy, residual breast cancer cell is not present in primary lesion and lymph node.

Time frame: Postoperation(within 26weeks after starting medication)

Changes of Ki67(%)

IHC is performed for formalin-fixed paraffin embedded tissue at the central laboratory. Ki67 is recorded as % and percentage reduction of baseline and Ki67 expressed cell on day28 are compared.

Time frame: Baseline-4week(second core needle biopsy)

Breast conservation rate

Before pre-operative anti hormone therapy, the patients are classified into following three types 1. Candidate for BCS 2. Marginal for breast conservation surgery 3. Candidate for mastectomy only 4. Inoperable by standard mastectomy Classification of each type shall be determined by each researcher of each institution subjectively. For future separate objective analysis, central institution will collect image file of mammography of each patient. Type of operation being actually performed in each type is compared. (BCS vs mastectomy)

Time frame: Baseline-postoperation(within 26weeks after starting medication)

Breast density change

Percent mammographic density (%) of cranial-caudal view of opposite breast is measured/compared based on continued variable by using validated computer-assisted thresholding program called Cumulus software (University Toronto, Toronto, Ontario, Canada).

Time frame: Baseline-24week(after completing medication, preoperatively)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.